Kerri-Ann Millar currently works at Cue Biopharma, Inc., as Chief Financial Officer from 2020. Ms. Millar also formerly worked at Flexion Therapeutics, Inc., as Controller from 2014 to 2017.

Cue Biopharma Inc是一家处于发展阶段的免疫治疗公司。该公司致力于开发用于选择性调节与疾病相关的T细胞亚群，以治疗癌症和自身免疫性疾病的生物制剂。其免疫肿瘤产品包括CUE-100框架和CUE-200框架；自身免疫性产品包括MHC I类项目和MHC II类项目。CUE-100框架限制 ...

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

Cue Biopharma (NASDAQ:CUE – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, April 14th. Analysts expect the company to announce earnings ...

In the fourth quarter of 2024, Cue Biopharma reported collaboration revenues of $1.6 million. The company's research and development (R&D) expenses were lower than anticipated at $7.2 million ...

Cue Biopharma (NASDAQ:CUE – Get Free Report) is expected to be posting its quarterly earnings results on Wednesday, March 26th. Analysts expect Cue Biopharma to post earnings of ($0.15 ...

Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08 ...